Pyrazoloquinolinone Ligands for Selective Alpha-6 GABAA Receptor Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compounds that modulate GABAA receptor activity, such as barbiturates and anesthetics, can be toxic at higher concentrations due to their ability to directly open the receptor channel in the absence of GABA, whereas benzodiazepines and pyrazoloquinolinones only allosterically modulate chloride flux, posing limitations in treating neurological disorders effectively.
Innovation Solution
Development of novel pyrazoloquinolinone compounds with selective modulatory activity at α6-GABAA receptors, which preferentially modulate GABA currents without directly opening the receptor channel, thereby reducing toxicity and enhancing therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If barbiturates and anesthetics are used to modulate GABAA receptor activity, then therapeutic effects are achieved, but toxicity increases at higher concentrations due to direct channel opening
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures that target particular binding sites on GABAA receptors. The pyrazoloquinolinone core structure with specific substituents at defined positions creates selective interaction with α6-containing receptors, achieving therapeutic effects while avoiding the non-selective toxic effects of barbiturates and anesthetics that act on multiple receptor subtypes.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters such as substituent types, positions, and stereochemistry to optimize receptor selectivity. By adjusting these molecular parameters, the compounds achieve high affinity for α6-GABAA receptors while maintaining low affinity for other subtypes, thereby separating therapeutic efficacy from toxicity.
2Object-affected harmful factors
If benzodiazepines and pyrazoloquinolinones are used to allosterically modulate chloride flux, then toxicity is reduced, but therapeutic efficacy is limited
Solution Approach 1:
The patent applies universality by designing compounds that can selectively modulate multiple GABAA receptor subtypes containing the α6 subunit (such as α6β2γ2, α6β3γ2, and α6δ receptors). This multi-functional selectivity allows the compounds to address various neurological conditions involving different α6-containing receptor populations, enhancing therapeutic efficacy while maintaining the safety profile of allosteric modulators.
3Reliability
If compounds are designed to directly open GABAA receptor channel, then potent therapeutic effect is achieved, but safety decreases due to toxic side effects
Solution Approach 1:
The patent applies the intermediary principle by designing compounds that act as positive allosteric modulators rather than direct channel openers. These compounds bind to allosteric sites on GABAA receptors and enhance the effect of endogenous GABA, producing therapeutic effects through modulation rather than direct activation. This intermediary mechanism of action provides a safety buffer, allowing therapeutic effects to be achieved without the toxic side effects associated with direct channel opening at high concentrations.
Data Source
AI summary
Provided herein are novel pyrazoloquinolinone compounds and method of using such compounds to treat disorders such as neuropsychiatric disorders with sensorimotor gating deficits, such as schizophrenia, tic disorders, attention deficit hyperactivity disorder, obsessive compulsive disorder, panic disorder, Huntington's disease and nocturnal enuresis; depression; temporomandibular myofascial pain; disorders of trigeminal nerve, such as trigeminal neuralgia and trigeminal neuropathy; migraine; and tinnitus.